Evaluation of the Safety of Antivipmyn registered in Humans

• Published in: Clinical toxicology (Philadelphia, Pa.) Pa.), 2007-05, Vol.45 (4), p.341-341
• Main Authors: Torres-Alanis, O, de la Tamez, OE, Garza-Ocanas, L, Reyes-Araiza, R, Tamez-Rodriguez, V, Garcia, U W, Canudas-Gonzalez, J
• Format: Article
• Language: English
• Subjects: Human immunodeficiency virus
• ISSN: 1556-3650

Antivipmyn registered is an anti-venom used in Mexico in case of poisonings by venomous snakes. Objective: In the present study we evaluated the safety of Antivipmyn registered in humans. Methods: Experimental protocol was approved by the Human Subjects Ethical Committee of our institution. Written informed consent was obtained from 14 (18-25 years) healthy volunteers. Clinical history, physical examination, vital signs, laboratory analyses (blood chemistry, hematology, urinalysis, HIV and hepatitis B), chest X-ray and EKG were carried out in all the cases before the study. The subjects received Antivipmyn registered by a 30 minutes intravenous infusion period (1 ampoule Antivipmyn registered dissolved in 100 ml of isotonic NaCl solution). Physical examination, vital signs and evaluation of systemic symptoms were carried out throughout the period of infusion and after 3,6,12 and 24-h. Three weeks after the first dose the subjects received a second dose of Antivipmyn registered and the same clinical parameters were evaluated. Laboratory analyses were made after the evaluation period. Results: Repeated physical examination performed during the study disclosed no abnormalities in any subject Antivipmyn registered had no significant effect on blood pressure, temperature, pulse and respiration and all clinical laboratory results were normal in all the cases. Conclusion: During die testing period no clinical drug-related symptoms were found in any subject after Antivipmyn registered intravenous administration.